首页> 外国专利> PROTEINFRAGMENTE DIE VERSCHIEDENE EPITOPE DER HPV PROTEINE E6 UND E7 UMFASSEN, IHRE HERSTELLUNG UND VERWENDUNGEN INSBESONDERE ZUR IMPFUNG

PROTEINFRAGMENTE DIE VERSCHIEDENE EPITOPE DER HPV PROTEINE E6 UND E7 UMFASSEN, IHRE HERSTELLUNG UND VERWENDUNGEN INSBESONDERE ZUR IMPFUNG

机译:蛋白质片段对HPV蛋白质E6和E7的不同表位,它们的生产和特别是在疫苗接种中的用途

摘要

Polyepitopic fragments (I) from the human p53 that is overexpressed in many types of cancers, are new. Polyepitopic fragments (I) from the human p53 that is overexpressed in many types of cancers, are new. (I) is contained within any of the sequences ThrTyrGlnGlySerTyrGlyPheArgLeuGlyPheLeuHisSerGlyThrAlaLysSerVal- ThrCysThrTyrSerProAlaLeuAsnLysMetPheCysGlnLeu; SerThrProProProGlyThrArgValArgAlaMetAlaIleTyrLysGlnSerGlnHisMet; GlyLeuAlaProProGlnHisLeuIleArgValGluGlyAsnLeuArgValGluTyrLeuAsp- AspArgAsnThrPheArgHisSerValValValProTyr; GlySerAspCysThrThrIleHisTyrAsnTyrMetCysAsnSerSerCysMet; ArgProIleLeuThrIleIleThrLeuGluAspSerSerGlyAsnLeuLeuGlyArgAsnSer- PheGluValArg. These represent, respectively, amino acids 102-137, 149-169, 187-212, 226-243 or 249-273 of p53, and bind stably to, respectively, the human leukocyte antigen (HLA) type molecules A2, A24 or B62; A2, A3, A24, B27, B35, or B62; A2, A24, B27 or B44; A1, A24 or B44; or A2, B27, B35, B44 or B62. Alternatively, (I) may be a derivative of the sequences, binding to the same HLA molecules as the parent compounds, formed by substitution, deletion and/or addition of one or more amino acids, modification of at least one peptide bond (particularly replacement by retro or retro-inverso bonds) and/or substitution of at least one amino acid by a non-proteinogenic amino acid. Independent claims are also included for the following: (1) nucleic acid (II) that encodes (I) or its derivatives; (2) mono- or poly-clonal antibodies (Ab) directed against (I) or its derivatives; and (3) pharmaceutical composition or vaccine containing at least one (I), or its derivative, (II) or Ab. - ACTIVITY : Cytostatic. No biological data is given. - MECHANISM OF ACTION : (I) induces a specific immune response; they induce cytolysis, by cytotoxic T cells (CTL), of cells that express (I) associated with appropriate HLA molecules and induce secretion of cytokines (particularly interleukins -2 and -4, and gamma -interferon) by these CTL; vaccine
机译:在许多类型的癌症中过表达的人p53多表位片段(I)是新的。来自人类p53的多表位片段(I)在许多类型的癌症中都过表达,这是新的。 (I)包含在任何序列ThrTyrGlnGlySerTyrGlyPheArgLeuGlyPheLeuHisSerGlyThrAlaLysSerVal- ThrCysThrTyrSerProAlaLeuAsnLysMetPheCysGlnLeu中; SerThrProProProGlyThrArgValArgAlaMetAlaIleTyrLysGlnSerGlnHisMet; GlyLeuAlaProProGlnHisLeuIleArgValGluGlyAsnLeuArgValGluTyrLeuAsp- AspArgAsnThrPheArgHisSerValValValProTyr; GlySerAspCysThrThrIleHisTyrAsnTyrMetCysAsnSerSerCysMet; ArgProIleLeuThrIleIleThrLeuGluAspSerSerGlyAsnLeuLe​​uGlyArgAsnSer- PheGluValArg。它们分别代表p53的氨基酸102-137、149-169、187-212、226-243或249-273,并分别与人白细胞抗原(HLA)型分子A2,A24或B62稳定结合; A2,A3,A24,B27,B35或B62; A2,A24,B27或B44; A1,A24或B44;或A2,B27,B35,B44或B62。或者,(I)可以是序列的衍生物,其与母体化合物结合到相同的HLA分子上,是通过取代,缺失和/或添加一个或多个氨基酸,修饰至少一个肽键(特别是置换)而形成的。 (通过逆向或逆向反向键)和/或至少一种氨基酸被非蛋白原性氨基酸取代。还包括以下方面的独立权利要求:(1)编码(I)或其衍生物的核酸(II); (2)针对(I)或其衍生物的单克隆或多克隆抗体(Ab); (3)包含至少一种(I)或其衍生物,(II)或Ab的药物组合物或疫苗。 -活动性:细胞抑制作用。没有给出生物学数据。 -作用机理:(I)诱导特异性免疫反应;它们通过细胞毒性T细胞(CTL)诱导表达与适当的HLA分子相关的(I)并诱导这些CTL分泌细胞因子(特别是白介素-2和-4和γ-干扰素)的细胞发生细胞溶解;疫苗

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号